INKT · MiNK Therapeutics Inc
United States · RS rating 24 · As of 2026-10-14
| Price | 10.35 USD |
|---|---|
| 1-day change | +1.2% |
| RS rating (overall / 1M / 3M / 12M) | 24 / 25 / 46 / 23 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 29 / 27 / 30 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -8.8% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +30.9% |
| Market cap (USD) | $53.3M |